GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » iX Biopharma Ltd (SGX:42C) » Definitions » Stock Based Compensation

iX Biopharma (SGX:42C) Stock Based Compensation : S$0.06 Mil (TTM As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is iX Biopharma Stock Based Compensation?

iX Biopharma's Stock Based Compensation for the six months ended in Dec. 2024 was S$0.03 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2024 was S$0.06 Mil.


iX Biopharma Stock Based Compensation Historical Data

The historical data trend for iX Biopharma's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iX Biopharma Stock Based Compensation Chart

iX Biopharma Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.54 1.00 1.38 0.86 -0.85

iX Biopharma Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.43 0.43 -0.88 0.03 0.03

iX Biopharma Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was S$0.06 Mil.


iX Biopharma Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of iX Biopharma's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


iX Biopharma Business Description

Traded in Other Exchanges
N/A
Address
1 Kim Seng Promenade, No. 14-01, Great World City East Lobby, Singapore, SGP, 237994
iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in United States of America, Singapore, Australia, and China, of which the majority of the revenue comes from the United States of America. The company generates the majority of its revenue from the sale of specialty pharmaceutical products.

iX Biopharma Headlines

No Headlines